Related Experiment Video
Updated: Mar 21, 2026

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
Published on: July 28, 2023
Current perspective in tuberculosis vaccine development for high TB endemic regions
Aliabbas A Husain1, Hatim F Daginawala1, Lokendra Singh1
1Biochemistry Research Laboratory, Central India Institute of Medical Sciences, 88/2 Bajaj Nagar, Nagpur 440 010, India.
Despite the Bacillus Calmette Guerin (BCG) vaccine, tuberculosis (TB) remains a global epidemic. This review explores strategies to enhance BCG efficacy and develop new vaccines for high TB regions.
Area of Science:
- Immunology
- Vaccinology
- Infectious Diseases
Background:
- Tuberculosis (TB) persists as a global health crisis, with the Bacillus Calmette Guerin (BCG) vaccine showing limited efficacy in high-incidence regions.
- Over six decades of BCG use highlight the need for improved TB vaccine strategies.
Purpose of the Study:
- To review current perspectives on TB vaccination research.
- To identify research strategies for enhancing BCG efficacy.
- To guide the development of new vaccines for TB-endemic areas.
Main Methods:
- Literature review of TB vaccination research.
- Analysis of BCG failure mechanisms.
- Examination of immune responses associated with TB protection.
Main Results:
- Current TB vaccine research focuses on understanding BCG limitations and protective immunity.
- Strategies to improve BCG and develop novel vaccines are under investigation.
Conclusions:
- Further research is crucial to enhance existing BCG vaccine efficacy.
- Development of novel, effective vaccines is essential for controlling TB in endemic regions.
Related Concept Videos
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Vaccinations

